Till startsida
To content Read more about how we use cookies on gu.se

Plan for using and disseminating the knowledge

The results of ComplexDis have been presented in scientific publications and meetings as well as by the media (newspapers, radio and television). As described below this includes the development of a potential drug in multiple sclerosis. There is also a ComplexDis website. Moreover, computational and bioinformatic tools have been made available in the public domain. The aim is that the project will result in the development of standardized analytical tools to analyze complex diseases. These have been or will be made available to the research community on the ComplexDis website.

The PI’s of WP1, WP5 and WP8 have organized international workshops in 2007-10 that disseminated the results.

Section 1 - Exploitable knowledge and its Use

ComplexDis. Workpackage 8. IP: Pablo Villoslada

Exploitable Knowledge (description)Exploitable product(s) or measure(s)Sector(s) of applicationTimetable for commercial usePatents or other IPR protectionOwner & Other Partner(s) involved
 1. New biomarkers for Multiple Sclerosis 1. Diagnostic kit 1. Biotechnology
2. Medical diagnosis
 2011Patent submitted 2009. Planned patent extension PCT 2010 1. Univ. of Navarra
2. Progenika Inc
 1. New therapeutic targets for Multiple Sclerosis 1. Therapeutic targets for developing new therapies 1. Biotechnology
2. Pharm
 2020Patent submitted 2009. Planned patent extension PCT 2010 1. Univ. of Navarra
2. Progenika Inc

Results from WP8 done in the lab of PI. Pablo Villoslada lead to the identification of a set of 13 genes associated with the prognosis of Multiple Sclerosis, being able to discriminate between good and bad outcome with an accuracy of 95%. Validation of the test was performed in collaboration with Progenika Inc, a SME biotech company from Bilbao, Spain with expertise in developing diagnostic kits for complex diseases based in genomics. These results were protected with a patent:

Researchers: Antonio Martínez Martínez, Ricardo Palacios Urtasun, Jorge Sepulcre Bernad, Laureano Simón Buela, Pablo Villoslada Díaz.
Title: Genetic markers for the prognosis of Multiple Sclerosis
PCT/ES 2008/000785
Owner: Instituto Científico y Tecnológico de Navarra S.A. (University of Navarra) and Progenika Biopharma
Date of priority: 18/12/2008

Now, we are performing an additional validation and planning to move to commercial exploitation as a diagnostic kit by licensing to Progenika in 2011. Although diagnosis of MS is not complex, being able to perform an accurate prognosis of the disease is a challenge. The development of diagnostic methods for predicting disease course will be of great importance for patients and doctors in order to take therapeutic decisions. For this reason, this new method would have good commercial opportunities. Currently there are no competing diagnostic kits in the market and other diagnostic technologies such as brain magnetic resonance, although valuable for the diagnosis, lack diagnostic accuracy for predicting the disease course. This technology is proprietary and with no third parties dependences.

In addition, these markers will be explore as therapeutic targets for MS. If results are promising, we have the expression of interest in such results from the SME biotech company Bionure pharma, a spin-off of the Hospital Clinic of Barcelona promoted by PI Pablo Villoslada. MS is one of the most active areas for development of new drugs and all major pharmas have a project in this disease. For this reason, validating these targets would be of interest of pharmas working in MS.

Section 2 – Dissemination of knowledge

Overview table

actual Dates
TypeType of audienceCountries addressedSize of audience Partner responsible /involved 
Press release
General publicHungary, Italy, Sweden Not known WP5, WP6 and WP7
ConferencesClinicians and biomedical researchersEurope and the USNot knownPartners from all WPs 
Publications Clinicians and biomedical researchersGlobalNot knownPartners from all WPs
Project web site General public, clinicians and biomedical researchers  GlobalNot knownPartners from all WPs 
Web based analytical programsClinicians and biomedical researchers GlobalNot knownWP1, WP2, WP3 

Since the last report conferences include the International Conference in Systems Biology in Gothenburg in which partners from WP5 and WP8 gave talks. Partners from WP1 and WP5 organized the Bertinoro symposium in clinical systems biology in 2009. In addition partners from the different WPs have contributed at international specialty conferences in Allergology and Neurology. The project has resulted in several publications since the last report. These include both original research articles and review articles that can be found at the ComplexDis website under the link Publications.


Page Manager: Johan Thompson|Last update: 8/31/2010

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?